Design of 9-beta-D-arabinofuranosyladenine (ara-A) transdermal delivery system for animal studies: regulation of drug concentration in vivo.
Transdermal delivery systems of 9-beta-D-arabinofuranosyladenine (ara-A), having controlling membranes of various permeabilities, were developed and applied to Azone-pretreated hairless mouse abdominal skin. It was confirmed that the blood concentrations of ara-A and its metabolite 9-beta-D-arabinofuranosylhypoxanthine (ara-H) in hairless mice are controlled by the permeability of the controlling membrane in the transdermal patch. Furthermore, these blood concentrations were found to closely agree with the values obtained from theoretical model calculations. Finally, but importantly, the "micropharmacokinetic" behavior of ara-A in cutaneous tissue could also be predicted. These results suggest that the transdermal patch may be employed in dermal and transdermal ara-A efficacy studies in the treatment of cutaneous herpes virus infections in hairless mice.
Komada
F
F
University of Utah, Salt Lake City, 84112.
Imanidis
G
G
Miyajima
M
M
Okano
T
T
Durrani
M J
MJ
Higuchi
W I
WI
Kim
S W
SW
Shannon
W M
WM
Baker
D C
DC
D000279:Administration, Cutaneous; D000818:Animals; D001087:Arabinonucleosides / Q000493:pharmacokinetics; D001381:Azepines / Q000494:pharmacology; D002855:Chromatography, Thin Layer; D066298:In Vitro Techniques; D051379:Mice; D008812:Mice, Hairless; D008954:Models, Biological; D012869:Skin Absorption / Q000187:drug effects; D014740:Vidarabine / Q000008:administration & dosage* / Q000493:pharmacokinetics
D001087:Arabinonucleosides; D001381:Azepines; C035229:laurocapram; C008099:hypoxanthine arabinoside; D014740:Vidarabine